Publications

Cardiometabolic research specialist announces Sandrine Claus appointment as Chief Scientific Officer to lead its microbiota-oriented ambitious strategy Bordeaux (France), 27th September 2017 – LNC Therapeutics, a company specialized in the research and development of gut microbiota directed drugs for the treatment of obesity and associated...

Variation in the human fecal microbiota has previously been associated with body mass index (BMI). Although obesity is a global health burden, the accumulation of abdominal visceral fat is the specific cardio-metabolic disease risk factor. Here, the authors explore links between the fecal microbiota and abdominal adiposity using body composition as...

Host genetics and the gut microbiome can both influence metabolic phenotypes. Here, Goodrich et al. compared microbiotas across >1,000 fecal samples obtained from the TwinsUK population, including 416 twin pairs. They identified many microbial taxa whose abundances were influenced by host genetics. The most heritable taxon, the family...

Evidence suggests the gut microbiome is involved in the development of cardiovascular disease (CVD), with the host-microbe interaction regulating immune and metabolic pathways. After correcting for age and gender, cross-validation analysis revealed that microbiota explain 4.5% of the variance in BMI, 6% in triglycerides, and 4% in high-density...